- Home
- ONFO vs VRAX Comparison
ONFO vs VRAX Comparison
Compare ONFO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- VRAX
- Stock Information
- Founded
- ONFO 2018
- VRAX 2013
- Country
- ONFO United States
- VRAX United Kingdom
- Employees
- ONFO N/A
- VRAX N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ONFO Technology
- VRAX Health Care
- Exchange
- ONFO Nasdaq
- VRAX Nasdaq
- Market Cap
- ONFO 6.7M
- VRAX 7.3M
- IPO Year
- ONFO 2022
- VRAX 2022
- Fundamental
- Price
- ONFO $1.31
- VRAX $1.87
- Analyst Decision
- ONFO
- VRAX
- Analyst Count
- ONFO 0
- VRAX 0
- Target Price
- ONFO N/A
- VRAX N/A
- AVG Volume (30 Days)
- ONFO 18.5K
- VRAX 304.3K
- Earning Date
- ONFO 11-15-2024
- VRAX 02-05-2025
- Dividend Yield
- ONFO N/A
- VRAX N/A
- EPS Growth
- ONFO N/A
- VRAX N/A
- EPS
- ONFO N/A
- VRAX N/A
- Revenue
- ONFO $6,590,171.00
- VRAX $84,872.00
- Revenue This Year
- ONFO $133.59
- VRAX $5,169.18
- Revenue Next Year
- ONFO N/A
- VRAX $66.97
- P/E Ratio
- ONFO N/A
- VRAX N/A
- Revenue Growth
- ONFO 29.25
- VRAX 7.03
- 52 Week Low
- ONFO $0.39
- VRAX $0.60
- 52 Week High
- ONFO $1.88
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- ONFO 48.15
- VRAX 48.66
- Support Level
- ONFO $1.35
- VRAX $1.65
- Resistance Level
- ONFO $1.48
- VRAX $2.10
- Average True Range (ATR)
- ONFO 0.11
- VRAX 0.22
- MACD
- ONFO 0.01
- VRAX 0.01
- Stochastic Oscillator
- ONFO 28.95
- VRAX 42.47
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.